Linsitinib (OSI-906) is one of these inhibitors, and it targets the tyrosine kinase domain of both IGF-1R and insulin-receptor (IR) [8], preventing tumor cell proliferation and inducing apoptosis [15]. Here, INSR is linked to neoplasm.